Race in a Bottle: The Story of BiDil and Racialized Medicine in a Post-Genomic Age

4.38 avg rating
( 8 ratings by Goodreads )
 
9780231162999: Race in a Bottle: The Story of BiDil and Racialized Medicine in a Post-Genomic Age
View all copies of this ISBN edition:
 
 

At a ceremony announcing the completion of the first draft of the human genome in 2000, President Bill Clinton declared, "I believe one of the great truths to emerge from this triumphant expedition inside the human genome is that in genetic terms, all human beings, regardless of race, are more than 99.9 percent the same." Yet despite this declaration of unity, biomedical research has focused increasingly on mapping that.1 percent of difference, particularly as it relates to race.

This trend is exemplified by the drug BiDil. Approved by the FDA in 2005 as the first drug with a race-specific indication on its label, BiDil was originally touted as a pathbreaking therapy to treat heart failure in black patients and help underserved populations. Upon closer examination, however, Jonathan Kahn reveals a far more complex story. At the most basic level, BiDil became racial through legal maneuvering and commercial pressure as much as through medical understandings of how the drug worked.

Using BiDil as a central case study, Kahn broadly examines the legal and commercial imperatives driving the expanding role of race in biomedicine, even as scientific advances in genomics could render the issue irrelevant. He surveys the distinct politics informing the use of race in medicine and the very real health disparities caused by racism and social injustice that are now being cast as a mere function of genetic difference. Calling for a more reasoned approach to using race in biomedical research and practice, Kahn asks readers to recognize that, just as genetics is a complex field requiring sensitivity and expertise, so too is race, particularly in the field of biomedicine.

"synopsis" may belong to another edition of this title.

Book Description:

Approved by the FDA in 2005, BiDil was originally touted as a pathbreaking therapy to treat heart failure in black patients and help underserved populations. Upon closer examination, Jonathan Kahn reveals BiDil became racial through legal maneuvering and commercial pressure as much as through medical understandings of how the drug worked. Using BiDil as a case study, Kahn broadly examines the distinct politics informing the use of race in medicine and the very real health disparities caused by racism and social injustice that are being cast as a function of genetic difference. Kahn shows that, just as genetics is a complex field requiring sensitivity and expertise, so too is race, particularly in the field of biomedicine.

About the Author:

Jonathan Kahn is professor of law at Hamline University School of Law. He holds a Ph.D. in United States history from Cornell University and a J.D. from the Boalt Hall School of Law, University of California, Berkeley. He is the author of Budgeting Democracy: State Building and Citizenship in America, 1897–1928.

"About this title" may belong to another edition of this title.

Other Popular Editions of the Same Title

9780231162982: Race in a Bottle: The Story of BiDil and Racialized Medicine in a Post-Genomic Age

Featured Edition

ISBN 10:  0231162987 ISBN 13:  9780231162982
Publisher: Columbia University Press, 2012
Hardcover

Top Search Results from the AbeBooks Marketplace

1.

Jonathan Kahn
ISBN 10: 0231162995 ISBN 13: 9780231162999
New Quantity Available: 1
Seller:
Books_Universe
(Sugarland, TX, U.S.A.)
Rating
[?]

Book Description Condition: New. Brand New. US Edition Book. We do not ship to Military Addresses. Fast Shipping with Order Tracking. For Standard Shipping 7-8 business days & Expedite Shipping 4-6 business days, after shipping. Seller Inventory # 0231162995-RMZ

More information about this seller | Contact this seller

Buy New
US$ 15.35
Convert currency

Add to Basket

Shipping: FREE
Within U.S.A.
Destination, rates & speeds

2.

Jonathan Kahn
ISBN 10: 0231162995 ISBN 13: 9780231162999
New Quantity Available: 1
Seller:
Fairview Books
(Southfield, MI, U.S.A.)
Rating
[?]

Book Description Condition: New. Brand New Book. Seller Inventory # 0231162995-RYX

More information about this seller | Contact this seller

Buy New
US$ 16.81
Convert currency

Add to Basket

Shipping: FREE
Within U.S.A.
Destination, rates & speeds

3.

Jonathan Kahn
ISBN 10: 0231162995 ISBN 13: 9780231162999
New Quantity Available: 5
Seller:
GreatBookPrices
(Columbia, MD, U.S.A.)
Rating
[?]

Book Description Condition: New. Seller Inventory # 20584832-n

More information about this seller | Contact this seller

Buy New
US$ 22.74
Convert currency

Add to Basket

Shipping: US$ 2.64
Within U.S.A.
Destination, rates & speeds

4.

Jonathan Kahn
Published by Columbia University Press, United States (2014)
ISBN 10: 0231162995 ISBN 13: 9780231162999
New Paperback Quantity Available: 10
Seller:
Book Depository International
(London, United Kingdom)
Rating
[?]

Book Description Columbia University Press, United States, 2014. Paperback. Condition: New. Language: English . Brand New Book. At a ceremony announcing the completion of the first draft of the human genome in 2000, President Bill Clinton declared, I believe one of the great truths to emerge from this triumphant expedition inside the human genome is that in genetic terms, all human beings, regardless of race, are more than 99.9 percent the same. Yet despite this declaration of unity, biomedical research has focused increasingly on mapping that.1 percent of difference, particularly as it relates to race. This trend is exemplified by the drug BiDil. Approved by the FDA in 2005 as the first drug with a race-specific indication on its label, BiDil was originally touted as a pathbreaking therapy to treat heart failure in black patients and help underserved populations. Upon closer examination, however, Jonathan Kahn reveals a far more complex story. At the most basic level, BiDil became racial through legal maneuvering and commercial pressure as much as through medical understandings of how the drug worked. Using BiDil as a central case study, Kahn broadly examines the legal and commercial imperatives driving the expanding role of race in biomedicine, even as scientific advances in genomics could render the issue irrelevant. He surveys the distinct politics informing the use of race in medicine and the very real health disparities caused by racism and social injustice that are now being cast as a mere function of genetic difference. Calling for a more reasoned approach to using race in biomedical research and practice, Kahn asks readers to recognize that, just as genetics is a complex field requiring sensitivity and expertise, so too is race, particularly in the field of biomedicine. Seller Inventory # AAH9780231162999

More information about this seller | Contact this seller

Buy New
US$ 27.14
Convert currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, rates & speeds

5.

Jonathan Kahn
Published by Columbia University Press, United States (2014)
ISBN 10: 0231162995 ISBN 13: 9780231162999
New Paperback Quantity Available: 10
Seller:
The Book Depository
(London, United Kingdom)
Rating
[?]

Book Description Columbia University Press, United States, 2014. Paperback. Condition: New. Language: English . Brand New Book. At a ceremony announcing the completion of the first draft of the human genome in 2000, President Bill Clinton declared, I believe one of the great truths to emerge from this triumphant expedition inside the human genome is that in genetic terms, all human beings, regardless of race, are more than 99.9 percent the same. Yet despite this declaration of unity, biomedical research has focused increasingly on mapping that.1 percent of difference, particularly as it relates to race. This trend is exemplified by the drug BiDil. Approved by the FDA in 2005 as the first drug with a race-specific indication on its label, BiDil was originally touted as a pathbreaking therapy to treat heart failure in black patients and help underserved populations. Upon closer examination, however, Jonathan Kahn reveals a far more complex story. At the most basic level, BiDil became racial through legal maneuvering and commercial pressure as much as through medical understandings of how the drug worked. Using BiDil as a central case study, Kahn broadly examines the legal and commercial imperatives driving the expanding role of race in biomedicine, even as scientific advances in genomics could render the issue irrelevant. He surveys the distinct politics informing the use of race in medicine and the very real health disparities caused by racism and social injustice that are now being cast as a mere function of genetic difference. Calling for a more reasoned approach to using race in biomedical research and practice, Kahn asks readers to recognize that, just as genetics is a complex field requiring sensitivity and expertise, so too is race, particularly in the field of biomedicine. Seller Inventory # AAH9780231162999

More information about this seller | Contact this seller

Buy New
US$ 27.69
Convert currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, rates & speeds

6.

Jonathan Kahn
Published by Columbia University Press (2014)
ISBN 10: 0231162995 ISBN 13: 9780231162999
New Softcover Quantity Available: 1
Seller:
Irish Booksellers
(Portland, ME, U.S.A.)
Rating
[?]

Book Description Columbia University Press, 2014. Condition: New. book. Seller Inventory # M0231162995

More information about this seller | Contact this seller

Buy New
US$ 28.06
Convert currency

Add to Basket

Shipping: FREE
Within U.S.A.
Destination, rates & speeds

7.

Jonathan Kahn
Published by Columbia University Press (2014)
ISBN 10: 0231162995 ISBN 13: 9780231162999
New Quantity Available: 13
Seller:
Books2Anywhere
(Fairford, GLOS, United Kingdom)
Rating
[?]

Book Description Columbia University Press, 2014. PAP. Condition: New. New Book. Shipped from UK in 4 to 14 days. Established seller since 2000. Seller Inventory # WI-9780231162999

More information about this seller | Contact this seller

Buy New
US$ 20.52
Convert currency

Add to Basket

Shipping: US$ 11.79
From United Kingdom to U.S.A.
Destination, rates & speeds

8.

Jonathan Kahn (author)
Published by Columbia University Press 2014-08-12, New York (2014)
ISBN 10: 0231162995 ISBN 13: 9780231162999
New paperback Quantity Available: 5
Seller:
Blackwell's
(Oxford, OX, United Kingdom)
Rating
[?]

Book Description Columbia University Press 2014-08-12, New York, 2014. paperback. Condition: New. Seller Inventory # 9780231162999

More information about this seller | Contact this seller

Buy New
US$ 27.21
Convert currency

Add to Basket

Shipping: US$ 7.86
From United Kingdom to U.S.A.
Destination, rates & speeds

9.

Jonathan Kahn
Published by Columbia University Press
ISBN 10: 0231162995 ISBN 13: 9780231162999
New Paperback Quantity Available: 13
Seller:
THE SAINT BOOKSTORE
(Southport, United Kingdom)
Rating
[?]

Book Description Columbia University Press. Paperback. Condition: New. New copy - Usually dispatched within 2 working days. Seller Inventory # B9780231162999

More information about this seller | Contact this seller

Buy New
US$ 27.01
Convert currency

Add to Basket

Shipping: US$ 9.09
From United Kingdom to U.S.A.
Destination, rates & speeds

10.

Jonathan Kahn
Published by Columbia University Press, United States (2014)
ISBN 10: 0231162995 ISBN 13: 9780231162999
New Paperback Quantity Available: 10
Seller:
Book Depository hard to find
(London, United Kingdom)
Rating
[?]

Book Description Columbia University Press, United States, 2014. Paperback. Condition: New. Language: English . This book usually ship within 10-15 business days and we will endeavor to dispatch orders quicker than this where possible. Brand New Book. At a ceremony announcing the completion of the first draft of the human genome in 2000, President Bill Clinton declared, I believe one of the great truths to emerge from this triumphant expedition inside the human genome is that in genetic terms, all human beings, regardless of race, are more than 99.9 percent the same. Yet despite this declaration of unity, biomedical research has focused increasingly on mapping that.1 percent of difference, particularly as it relates to race. This trend is exemplified by the drug BiDil. Approved by the FDA in 2005 as the first drug with a race-specific indication on its label, BiDil was originally touted as a pathbreaking therapy to treat heart failure in black patients and help underserved populations. Upon closer examination, however, Jonathan Kahn reveals a far more complex story. At the most basic level, BiDil became racial through legal maneuvering and commercial pressure as much as through medical understandings of how the drug worked. Using BiDil as a central case study, Kahn broadly examines the legal and commercial imperatives driving the expanding role of race in biomedicine, even as scientific advances in genomics could render the issue irrelevant. He surveys the distinct politics informing the use of race in medicine and the very real health disparities caused by racism and social injustice that are now being cast as a mere function of genetic difference. Calling for a more reasoned approach to using race in biomedical research and practice, Kahn asks readers to recognize that, just as genetics is a complex field requiring sensitivity and expertise, so too is race, particularly in the field of biomedicine. Seller Inventory # BTE9780231162999

More information about this seller | Contact this seller

Buy New
US$ 38.53
Convert currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, rates & speeds

There are more copies of this book

View all search results for this book